Stories

The IRE Resource Center is a major research library containing more than 27,000 investigative stories.

Most of our stories are not available for download but can be easily ordered by contacting the Resource Center directly at 573-882-3364 or rescntr@ire.org where a researcher can help you pinpoint what you need.

Search results for "diabetes" ...

  • inewsource: Hustling Hope

    inewsource spent months investigating how a California lawyer built a national network of Trina Health clinics to perform what he calls a “miraculous” treatment for reversing the complications of diabetes, even though medical experts consider it a scam that harms patients. Senior healthcare reporter Cheryl Clark tells the story of a couple in rural Montana who invested their life savings into opening their own clinic, in part so the husband could get the treatments locally for his diabetes. Less than two years later, the clinic was shuttered as health insurers refused to pay for the treatment and its founder came under federal investigation. He pleaded guilty in January 2019 to public corruption charges related to his Trina Health operation in Alabama.
  • Questionable drugs

    These stories examined how the FDA approved cancer and diabetes drugs over the last decade. It found that in 74% of cancer drug approvals and all diabetes drug approvals, the decision to allow the drugs on the market was based on surrogate measures of effectiveness such CT scans or blood tests rather than real clinical outcomes such as improved survival or reductions in heart attacks, strokes or blindness.
  • Indian Drug Company Investigation

    The first part of our story profiled a whistleblower who exposed massive fraud at Ranbaxy, a multi-billion dollar Indian generic drug company that sold adulterated drugs to millions of Americans for years. The company sold these drugs to millions of Americans while lieing to the FDA claiming the drugs worked and could fight such life threatening illnesses like cancer, AIDS, diabetes and infections. The second part of our story revealed that despite the company’s claims, the company has ongoing serious manufacturing problems. In fact, just two weeks after CBS left a Ranbaxy plant in India, the FDA banned all finished drugs coming into the US from Ranbaxy. However, our story also revealed that while the FDA banned all finished drugs, the company is still continues to make the key ingredients for drugs sold to Americans today– including such popular drugs as Astra Zeneca’s Nexium. At the center of our story was the whistleblower, Dinesh Thakur, who had never done a television interview. The risks that Thakur took in exposing his company led to a massive federal false claims lawsuit that aided the federal criminal investigation and rewarded Thakur with $49 million. According to one federal agent who worked on the case for seven years, without Thakur “there would have been no investigation and no criminal conviction.” We were alarmed to find in our reporting that so many of the key players in the federal investigation had made personal decisions based on what they learned to never take a Ranbaxy drug. Three Justice Department attorneys, six former Ranbaxy employees, one former FDA criminal investigator and two Congressional investigators (Democrat and a Republican) all told CBS News that they would never take a Ranbaxy drug, nor would they allow a family member to do so. Each shared with us personal anecdotes of finding Ranbaxy drugs in family members’ medicine cabinets or receiving a prescription at a drug store only to tell the pharmacist that they must have a different brand. For this reason we felt strongly that it was important to notify our audience of the risks with this company. We also informed our audience that foreign drug makers are not subject to the same strong oversight that drug makers in the US face every day. For example, drug makers in the US face unannounced inspections. Despite efforts to beef up foreign FDA inspections, foreign companies are still notified in advance of upcoming inspections. In the US there is one FDA inspector for every 9 phamaceutical facilities. In India there is one FDA inspector for every 105 facilities. CBS News also tracked down half a dozen other former Ranbaxy employees who told CBS what they witnessed at the company both in the United States and in India. Two top employees went on camera to share their experiences.
  • Diabetes Test Strip Resale: A Million-Dollar Grey Market

    Diabetes is an epidemic in the US. It’s also a billion dollar industry. One of the most important aspects of diabetes care is a one-time use plastic strip that patients use to monitor their blood sugar. An investigation by KUOW Public Radio found that this little plastic strip is at the center of a million dollar grey market.
  • Divided Loyalties

    A look at how nonprofit health information and advocacy groups are taking millions of dollars from druge and medical device makers. Organizations such as the American Diabetes Association and the National Osteporosis Foudndation are involved in this debate of drug safety.
  • Hidden Risks, Lethal Truths

    This story was initially reported in June of 2000, when the dangerous effects of the diabetes pill, Rezulin, were first discovered by the U.S. Food and Drug Administration. The pill, which was found to cause liver-related deaths in patients, was finally taken off the market in March 2000 after bringing in $2.1 billion in sales for Warner-Lambert Co. This investigation looks at internal documents which uncover Warner-Lambert executives hid early indications of the drug's effects from regulators. The documents also indicate that the company put off sharing the information with family doctors prescribing the medicine with their patients.
  • Blackout

    Halsne found that Washington drivers with severe medical impairments, such as diabetes, were again and again given immunity following serious auto accidents. Washington law does not restrict licenses of drivers who have a long history of blackouts. KIRO-TV profiled a diabetic who sent a total of 9 innocent victims to the hospital in 3 car wrecks. KIRO found eight-thousand medically impaired drivers are allowed to keep their licenses year after year.
  • Pitch to Switch: Bristol-Myers Fights To Lock In Patients Before Generics Hit

    The Wall Street Journal looks at Bristol-Myers' fight to woo patients to a new diabetes medication that isn't substantially different, but is shielded from generic competition. "If the aggressive marketing campaign succeeds, it could mean that tens of thousands of elderly and poor patients--groups for which diabetes has reached epidemic proportions--will keep using the high-priced alternatives from Bristol-Myers."
  • Who owns my disease

    Mother Jones reports on an unprecedented effort of a family to deal with their children's congenital defect by patenting the gene for the disease. "The Terrys have gained something no other family or patient group now has: a way to make sure that the genetics revolution benefits those with the most at stake," the magazine reveals. The story examines a recent pattern of genetic patents impeding new science developments, and looks at the efforts of various nonprofit groups to run their own scientific programs, funding researchers directly.
  • Dangerous Drugs

    A CBS News investigation into the FDA reveals that the organization has approved a number of drugs despite objections from its own scientists. Among the questionably approved drugs was Rezulin, a diabetes drug, and Relenza, a flu drug. "The series exposed a serious rift between FDA rank-and-file scientists who felt their concerns were being ignored, and FDA executives who repeatedly sided with pharmaceutical companies over issues of safety regarding controversial drugs."